{
    "nct_id": "NCT03787602",
    "official_title": "A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients With p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination With Avelumab in MCC Patients Who Are Anti-PD-1 or Anti-PD-L1 Treatment NaÃ¯ve",
    "inclusion_criteria": "* For Cohort 1, 3 and 4 patients must have failed treatment with at least one PD-1 inhibitor or PD-L1 inhibitor for metastatic MCC\n* For Cohort 2, patients must not have received any anti-PD-1 or anti-PD-L1 therapy\n* For Cohort 3, patients must not have received any prior chemotherapy\n* For Cohort 4, patients must have received at least one prior line of chemotherapy\n* ECOG performance status of 0 to 1\n* Histologically confirmed MCC. Disease must be measurable, with at least 1 measurable lesion by RECIST 1.1\n* MCC expressing p53WT based on any CLIA or test approved by local health authority or a validated test (Cohort 1 and 2)\n* MCC expressing p53WT based Central Lab test (Cohort 3 and 4)\n* Adequate hematological, hepatic, and renal functions\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* For Cohort 2, subjects must not have autoimmune disease, medical conditions requiring systemic immunosuppression, prior stem cell transplant, or active infection with HBV or HCV.\n* Patients previously treated with MDM2 antagonist therapies or p53-directed therapies\n* History of major organ transplant\n* Patients with known central nervous system (CNS) metastases that are previously untreated\n* Grade 2 or higher QTc prolongation (>480 milli-seconds per NCI-CTCAE criteria, version 5.0)",
    "miscellaneous_criteria": ""
}